Sign in Subscribe
Cable television broadcasting industry

CanSinoBIO's Recombinant Adenovirus Vector Vaccine Shows Promising Results

Strategic Insights

— 2 min read

CanSinoBIO's CEO, Yu Xuefeng, has highlighted the advantages of the company's recombinant adenovirus vector COVID-19 vaccine, which has been granted emergency use approval in China and authorized by the US FDA. The vaccine's use of a mild and safe adenovirus vector, which does not replicate on its own in the body and does not pose a risk for infection, has been praised as an improvement over traditional inactivated vaccines. The company's vaccine has shown a 90.98% efficacy rate in preventing severe disease and 65.7% effectiveness in preventing symptomatic diseases, with no serious adverse effects associated with the vaccine in phase III clinical trials. CanSinoBIO's vaccine is suitable for people aged 18 and older, including those aged 55 and older, and can be stored and transported at temperatures between 2 and 8°C for at least one year.

Key Takeaways:

  • CanSinoBIO's recombinant adenovirus vector COVID-19 vaccine has been granted emergency use approval in China and authorized by the US FDA, making it the first single-dose COVID-19 vaccine approved in the US.
  • The vaccine uses a mild and safe adenovirus vector, which does not replicate on its own in the body and does not pose a risk for infection, and can be produced in a safer and easier way than traditional inactivated vaccines.
  • The vaccine has shown a 90.98% efficacy rate in preventing severe disease and 65.7% effectiveness in preventing symptomatic diseases, with no serious adverse effects associated with the vaccine in phase III clinical trials.
  • CanSinoBIO's vaccine is suitable for people aged 18 and older, including those aged 55 and older, and can be stored and transported at temperatures between 2 and 8°C for at least one year.
  • Phase II clinical trials targeting children between the ages of 6 to 18 and pregnant women are still underway in China, with no data available yet.
  • CanSinoBIO's CEO, Yu Xuefeng, has stated that the company is capable of upgrading the vaccine to address potential mutations of the coronavirus, with a goal of quickening the production process to ensure timely delivery.
  • International partnerships, such as with Mexico and Pakistan, will accelerate the vaccine rollout and aid in public awareness about the vaccine's effectiveness.

Statistics:

  • 90.98% efficacy rate in preventing severe disease
  • 65.7% effectiveness in preventing symptomatic diseases
  • 72% effectiveness in the US
  • 86% protection against severe forms of the disease in the US
  • 44,000 people tested in the US, South Africa, and Latin America
  • 66.1% effective against moderate to severe/critical COVID-19 infections for at least four weeks after vaccination globally
  • 500 million doses expected to be produced in 2021

Sources:

  • Global Times: "China approves CanSinoBIO's COVID-19 vaccine for emergency use"
  • Global Times: "CanSinoBIO COVID-19 vaccine shows 90.98% efficacy rate"
  • CNN: "FDA authorizes Johnson & Johnson's COVID-19 vaccine"
  • China's National Medical Products Administration website
  • Xinhua: "Mexico receives first shipment of active substance needed for CanSinoBIO vaccine"

Read more